Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: Results from the gruppo oncologico nord ovest randomized trial

Cancer

Volumn 101, Issue 4, 2004, Pages 704-712

  Conte, Pier Franco ^a,h   Guarneri, Valentina ^a   Bruzzi, Paolo ^b   Prochilo, Tiziana ^a   Salvadori, Barbara ^a   Bolognesi, Angelo ^c   Aldrighetti, Daniela ^c   Venturini, Marco ^b   Rosso, Riccardo ^b   Mammoliti, Serafina ^d   Carnino, Flavio ^e   Giannessi, Piergiorgio ^f   Costantini, Massimo ^b   Moyano, Alfredo ^g   Baldini, Editta ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Divisione di Medicina II   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e S ANNA HOSPITAL   (Italy)

^f Department of Surgery   (Italy)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Concomitant administration; Epirubicin; Metastatic breast carcinoma; Paclitaxel; Sequential administration

Indexed keywords

CIPROFLOXACIN; DEXAMETHASONE; DIPHENHYDRAMINE; EPIRUBICIN; FLUCONAZOLE; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HEPATORENAL SYNDROME; HUMAN; HYPOTHESIS; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUROPATHY; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NERVOUS SYSTEM DISEASES; NEUTROPENIA; PACLITAXEL; QUALITY OF LIFE;

EID: 3543147151     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20400     Document Type: Article

References (41)

1. Ramirez AJ, Towlson KE, Leaning MS, Richards MA, Rubens RD. Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer. 1998;78:1488-1494.
2. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197-2205.
3. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688-2699.
4. Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol. 2001;12:1067-1073.
5. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996;7:687-693.
6. Amadori D, Frassineti GL, Zoli W, et al. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Ann Oncol. 1996;23:16-22.
7. Conte PF, Baldini E, Gennari A, et al. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol. 1997;15:2510-2517.
8. Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol. 1999;17:3596-3602.
9. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997;15:1906-1915.
10. Danesi R, Conte PF, Del Tacca M. Pharmakokinetic optimization of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokinet. 1999;37:195-211.
11. Venturini M, Lunardi G, Del Mastro L, et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol. 2000;18:2116-2125.
12. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel, as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588-592.
13. Nabholtz JM, Falkson G, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer: results of a randomised, multicenter, phase III trial. J Clin Oncol. 2003;21:968-975.
14. Luck HJ, Thomssen C, Untch M, et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC): epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC): a study of the AGO breast cancer group [abstract]. Proc Am Soc Clin Oncol. 2000;19:73a.
15. Carmichael J: UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer [abstract 84]. Proc Am Soc Clin Oncol. 2001;20:22a.
16. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter trial. J Clin Oncol. 2001;19:1707-1715.
17. Mackey JR, Paterson A, Dirix L, et al: Final results of the phase III randomised trial comparing docetaxel (T), doxorubicin (A), and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol. 2002;21:35a.
18. Bonneterre J, Dieras V, Tubiana-Hulin M, et al. 6 cycles of epirubicin/docetaxel (ET) versus 6 cycles of 5FU/epirubicin/cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment [abstract]. Proc Am Soc Clin Oncol. 2001;20:42a.
19. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol. 2002;20:3114-3121.
20. Tubiana-Hulin M, Bonneterre J, Bougnoux P, et al. Better survival with epirubicin-docetaxel (ET) combination as first-line chemotherapy in patients with metastatic breast cancer (MBC): final results of a phase II randomized study [abstract 182]. Proc Am Soc Clin Oncol. 2003;22:46.
21. Bontenbal M, Braun JJ, Creemers JG, et al. Phase III study comparing AT (Adriamycin, docetaxel) to FAC (fluorouracil, Adriamycin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC) [abstract 201]. Eur J Cancer. 2003;1:5.
22. Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine/epirubicin/ paclitaxel (GET) vs 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer (MBC): demographics of a randomized, multicenter phase III trial of the Central European Cooperative Oncology Group (CECOG) [abstract 26]. Proc Am Soc Clin Oncol. 2003;22:7.
23. Koroleva I, Wojtukievicz M, Zaluski J, et al. Preliminary results of a phase II randomized trial of Taxotere (T) and doxorubicin (D) given in combination or sequentially as first line chemotherapy (CT) for metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol. 2001;20:30a.
24. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 1998;16:3720-3730.
25. Alba E, Martin M, Ramos M, et al. Multicenter phase III randomized trial comparing sequential versus concomitant administration of doxorubicin (A) and docetaxel (T) as first-line treatment of metastatic breast cancer (MBC). GEICAM 9903 Study [abstract 27]. Proc Am Soc Clin Oncol. 2003;22:8.
26. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001;19:602-611.
27. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 1996;14:1146-1155.
28. Michelotti A, Venturini M, Tibaldi C, et al. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Res Treat. 2000;59:133-139.
29. Winer EP, Berry DA, Woolf S. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial G362. J Clin Oncol. 2004;22;2061-2068.
30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
32. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods [published erratum appears in BMJ. 1996;313(7056):550]. BMJ. 1996;313(7048):36-39.
33. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods [published erratum appears in BMJ. 1996;313(7056):550]. BMJ. 1996;313(7048):36-39.
34. James Hung HM, Wang SJ, Tsong Y, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med. 2003;22:213-225.
35. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001;93:979-989.
36. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
37. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
38. Robert N, Leyland-Jones B, Asmar L, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer [abstract]. Breast Cancer Res Treat. 2002;76:s37.
39. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study [abstract 25]. Proc Am Soc Clin Oncol. 2003;22:7.
40. Fountzilas G, Papadimitriou C, Dafni U, et al. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2001;19:2232-2239.
41. Miller KD, McCaskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomised pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999;17:3033-3037.